indication

Substance-Related Disorders

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
7
7 approved · 0 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
77 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Clozapine
US-approved 1989 · Clozaril
Phase 44 trials
OwnerShanghai Mental Health Center
Protection2028
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 43 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 43 trials
OwnerAstraZeneca
Protection—
drugWithdrawn
Paliperidone
US-approved 2006 · Erzofri extended-release
—1 trial
OwnerJohnson & Johnson
Protection2041
drugCompleted
Brexpiprazole (Rexulti)
US-approved 2015 · Rexulti
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2033
drugUnknown
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 41 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041

Market size

prevalence as a range, not a number